Table 1.
Baseline characteristics of postmenopausal women with severe osteoporosis
| TPTD-ALN group (N = 202) |
ALN group (N = 357) |
|
|---|---|---|
| Age, y | 81.2 ± 4.3 | 81.5 ± 4.7 |
| Age at menopause, y | 49.5 ± 4.2 | 49.3 ± 4.3 |
| BMI, kg/m2 | 22.3 ± 3.7 | 22.3 ± 3.4 |
| Number of prevalent vertebral fractures | 1.8 ± 2.0 | 1.9 ± 2.1 |
| 0 | 30.2% | 30.8% |
| 1 | 27.7% | 24.9% |
| 2 | 15.8% | 15.4% |
| 3 | 10.4% | 10.1% |
| 4 | 5.4% | 6.7% |
| 5 or more | 10.4% | 12.0% |
| Maximum grade of prevalent vertebral fractures | ||
| Grade 1 | 10.4% | 9.0% |
| Grade 2 | 16.3% | 19.0% |
| Grade 3 | 43.1% | 41.2% |
| History of hip fractures, yes, % | 14.4% | 12.9% |
| L2-4 BMD, T-score | −2.3 ± 1.4 | −2.4 ± 1.4 |
| L2-4 BMD, < −2.5 SD, % | 46.3% | 53.0% |
| Total hip BMD, T-score | −2.74 ± 0.99 | −2.79 ± 1.04 |
| Total hip BMD, < −2.5 SD, % | 59.0% | 61.2% |
| Femoral neck BMD, T-score | −3.28 ± 1.01 | −3.15 ± 1.06 |
| Femoral neck BMD, < −2.5 SD, % | 77.9% | 76.4% |
| Prior treatment for osteoporosis, yes, % | 55.4% | 58.0% |
| Prior bisphosphonates, yes, % | 29.7% | 31.7% |
Values are shown as means ± SD or percentages. BMI body mass index; BMD bone mineral density; SD standard deviation; TPTD teriparatide; ALN alendronate